GlassScriptPhysician profile
Mark Randall Jennings
NPI 1003915539
$759.38
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $573 · 2020: $94.89 · 2021: $44.14 · 2022: $47.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $230.89 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $144.21 | 2019-2021 | |
| Novo Nordisk INC | $97.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $81.39 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.56 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $50.36 | 2019-2022 | |
| Amarin Pharma, INC. | $19.06 | 2019 | |
| Shire North American Group INC | $16.38 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.86 | 2019 | |
| Amgen INC. | $15.25 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.70 | 2019 | |
| Merck Sharp & Dohme LLC | $12.09 | 2019 | |
| Glaxosmithkline, LLC. | $10.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Jennings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.